HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Nexxus and Tresemme fueled a 9.2% increase in global consumer products sales to $360 mil. during the third quarter (ended June 30), and earnings before income taxes for the unit advanced 9.2% to $32.6 mil., Alberto announces July 27. The beauty supply business, which includes Sally Beauty and Beauty Systems Group, had sales of $599.5 mil., representing growth of 4%, while earnings before income taxes for the division were up 8.6% to $65.5 mil. Alberto's net sales in Q3 increased 6% to $952.7 mil. Due to a $50 mil. termination fee associated with the failed merger of Alberto's beauty supply business with Regis Corporation, Alberto's net earnings plummeted 42.9% to $30.5 mil., including non-core items. Alberto recently announced it will spin off Sally as a separate entity in a transaction expected to close in December (1"The Rose Sheet" June 26, 2006, p. 3)...

You may also be interested in...

Alberto-Culver Eyes Acquisitions Following Sally Spin-Off

Alberto-Culver's consumer products division will make acquisitions a top priority following the spin-off of Sally Beauty Company, the firm stated during a June 19 call announcing the decision

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts